The FDA cleared marketing for the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.

The FDA has granted 510(k) marketing clearance to the first in vitro blood-based biomarker diagnostic device for Alzheimer’s ...

Fujirebio Diagnostics Inc.’s Alzheimer’s disease assay received the U.S. FDA’s first clearance for a blood test for the ...

The US Food and Drug Administration has cleared the first-ever blood test for diagnosing Alzheimer's disease, offering a less ...

The test has a complicated name: The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio. But the goal of the test, created by ...

The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer’s disease, ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

The test is for those aged 55 and older who are already exhibiting signs and symptoms of the disease, the FDA says.

The new test, known as the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, detects amyloid plaques through blood testing, a ...

Improvements in diagnostics for the early detection of Alzheimer's disease have the potential to transform patient care and ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The FDA cleared the first blood test intended to help in diagnosing Alzheimer’s, marking a significant step in making diagnosis more accessible and less invasive. The test is designed for adults 55 ...